Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warner-Lambert/Glaxo

This article was originally published in The Tan Sheet

Executive Summary

Finalize joint venture to develop, seek approval and market over-the-counter versions of Glaxo prescription drugs, initially focusing on an Rx-to-OTC switch of Zantac (ranitidine). Warner- Lambert and Glaxo announced a letter of intent agreement to form the joint venture in July ("The Tan Sheet" Aug. 2, p. 4). The entity will be managed by a soon-to-be-announced committee of representatives from each company, with day-to-day operations being handled by Warner-Lambert. Warner-Welcome, a separate joint venture formed with Burroughs Wellcome, will market OTC products arising from the GIaxo/W-L deal.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082290

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel